Tan and colleagues found that augmented PP2A-B55β expression stabilizes cyclin E1 and promotes its overexpression in cancer-derived cell lines and breast tumors, suggesting PP2A-B55b–directed therapies might be particularly effective for the treatment of highly aggressive basal-like TNBCs, whose growth and survival have been shown to depend on these abnormalities [39,43]. This evidence concerns the gene CCNE1 and cancer.